Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study.

Ther Adv Neurol Disord · 2025 · PMC11811979 · PMID 39935588

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a small trendno p-value reported

In TOPAZ, there was a small trend toward improved household productivity in participants treated with alemtuzumab, seen as a decrease in the mean hours lost in Year 5 (6.11) compared with baseline (8.57), and an increase in mean work output in household chores in Year 2 (21.22%) relative to baseline (16.08%) ( Figure 10(a) and ( b )).

also in 180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.